Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nektar Therapeutics (NKTR) SEC filings page brings together the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nektar’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Capital Market, and its filings provide structured insight into clinical progress, capital markets activity and corporate governance.
Recent Form 8-K reports include detailed descriptions of topline results from the Phase 2b REZOLVE-AD trial in atopic dermatitis and the Phase 2b REZOLVE-AA trial in alopecia areata, including study design, patient populations, primary and secondary endpoints, and summarized efficacy and safety outcomes. Other 8-K filings cover financial results for completed quarters, underwritten equity offerings under an effective shelf registration statement, and notices related to Nasdaq minimum bid price compliance.
Through these filings, investors can review how Nektar characterizes rezpegaldesleukin (REZPEG, or NKTR-358) as a first-in-class regulatory T cell stimulator and IL-2 pathway agonist, and how it describes additional pipeline programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. Filings also outline FDA Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as risk factor language and forward-looking statement disclaimers that frame development and regulatory uncertainty.
On Stock Titan, these SEC documents are updated as they are made available on EDGAR. AI-powered tools can help explain key sections of Nektar’s 8-Ks and related reports in plain language, highlight important clinical and financing disclosures, and surface items such as listing status updates and material agreements. This allows readers to quickly understand the implications of new filings for Nektar’s immunology pipeline and its Nasdaq-listed equity.
Nektar Therapeutics (NKTR) Form 144 notice reports a proposed sale of 725 common shares held in a brokerage account at Fidelity Brokerage Services. The shares were acquired through restricted stock vesting on 08/15/2025 and were paid as compensation. The filer lists an approximate sale date of 08/19/2025 on the NASDAQ; the aggregate market value at that date is shown as $19,277.83. The filing states there were no securities sold in the past three months by the same person and includes the standard representation that the seller knows of no undisclosed material adverse information.
Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 709,761 shares of Nektar Therapeutics common stock, representing 5.72% of the class as of June 30, 2025. The filing states all shares are held by funds and separately managed accounts under Nantahala's control and that each reporting person has shared voting and dispositive power over those shares and no sole voting or dispositive power. The statement certifies the shares were acquired and are held in the ordinary course of business and not with the purpose of changing or influencing control of the issuer.
Nektar Therapeutics has a group of related reporting persons — TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and individual Chen Yu — that together report beneficial ownership of 1,933,333 shares of common stock, representing 9.3% of the class on a fully reported basis. The disclosed position consists of 266,666 shares held of record and 1,666,667 shares issuable upon exercise of pre-funded warrants held of record by the reporting vehicle. The filing states the holdings are shared voting and dispositive power and references 19,018,573 shares outstanding used in the percentage calculation. The statement confirms the position was not acquired to change or influence control.
Nektar Therapeutics (Nasdaq: NKTR) filed an 8-K announcing that Nasdaq has formally confirmed the company has regained compliance with Listing Rule 5550(a)(2). The June 24 2025 letter follows ten consecutive business days—ending June 23—during which NKTR’s common stock closed at or above $1.00, satisfying the Minimum Bid Price Rule. The original deficiency notice was dated April 3 2025 and had provided until September 30 2025 to cure. With the requirement met, the deficiency matter is closed and no further action is required. No additional financial data were disclosed beyond the Inline XBRL cover page.
The filing removes an immediate delisting threat and lowers listing-related risk for shareholders.